[HTML] frontiersin.org

[HTML][HTML] The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study

CC Yang, YW Tsai, SH Wang, JY Wu, TH Liu… - Frontiers in …, 2024 - frontiersin.org
Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …
被引用次数：1 相关文章

The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study

CC Yang, YW Tsai, SH Wang, JY Wu… - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …

The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study.

CC Yang, YW Tsai, SH Wang, JY Wu… - Frontiers in …, 2024 - europepmc.org
Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …
[HTML] nih.gov

[HTML][HTML] The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study

CC Yang, YW Tsai, SH Wang, JY Wu… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …
[HTML] frontiersin.org

[HTML][HTML] The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study

CC Yang, YW Tsai, SH Wang, JY Wu, TH Liu… - Frontiers in …, 2024 - frontiersin.org
Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …